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background:  Triple therapy with ASA, clopidogrel and warfarin (ACW) is associated with increased bleeding, but there is no data that evaluates 
whether clopidogrel and warfarin without ASA (CW) is sufficient in preventing stent thrombosis (ST). This study tested whether omitting ASA in 
patients on warfarin and clopidogrel who received either BMS or DES was effective and decreased bleeding.
methods:  396 consecutive patients undergoing PCI at a single urban center were enrolled. All were discharged on clopidogrel 75 mg. Patients 
already on warfarin were continued. The choice to start ASA 325 mg was at the discretion of the cardiologist. Patients were followed for at least 1 
year. The drug regimen selected was maintained for at least 1 month after BMS and 1 year after DES. Primary endpoints were all-cause mortality, MI, 
stroke, ST, target vessel revascularization. Secondary endpoints included bleeding events.
results:  The indication for warfarin was AF in 74% and mechanical valve 12%; the remainder included VTE, severe systolic dysfunction, and the 
presence of LV thrombus. 48% of patients had DM. Multivariate analyses showed DM to be a statistically significant determinant of ST. 
Conclusions:  CW is not effective in preventing ST in DM patients requiring warfarin. ACW reduces the incidence of ST and lowers all-cause 
mortality but with increased bleeding. Importantly, CW prevents ST in non-DM patients who require warfarin with less bleeding events, and may be 
the preferred antithrombotic therapy in this subgroup.
 
